The Future is Bright for Specialized Phototherapy
Building on over 20 years of research, our proprietary specialized phototherapy technology delivers breakthrough therapeutic benefits for people with Parkinson’s disease.
While previous short-term light therapy trials have demonstrated varying degrees of improvement in motor and non-motor symptoms in Parkinson’s disease, PhotoPharmics supported pilot trials to better understand the effects of various wavelengths, intensities, and session frequency of light administration. Click here for a complete list of referenced articles.
Our research yielded a light administration protocol and a combination of intensities and wavelengths now embodied in our specialized light therapy medical device called Celeste®. Placed at arm’s length and bathing the user’s face in light, this treatment is both convenient and non-invasive and promises to be effective in improving motor and non-motor function and quality of life for people with Parkinson’s disease and promises improvement in other neurodegenerative diseases.
Completed 92 Patient Trial
PhotoPharmics organized and conducted a multi-national, randomized, double-blind, controlled trial involving 92 patients to assess the safety and efficacy of our specialized phototherapy, non-drug treatment for motor and non-motor symptoms in Parkinson’s disease. Learn more at clinicaltrials.gov (#NCT02175472).
- Safety. As anticipated, no specific serious adverse events were reported in the trial. Patients experienced only benign and transitory side effects.
- Efficacy. Although the study missed statistical significance in its primary endpoint, our treatment demonstrated clinically meaningful improvement in quality of life and combined motor and non-motor function. Preliminary trial results can be viewed here.
NEW! Upcoming Pivotal Trial
PhotoPharmics is steadily moving specialized phototherapy forward to become a standard of care in Parkinson’s disease. PhotoPharmics announced a 300-patient pivotal trial to establish the efficacy of the next generation of our specialized phototherapy treatment.
Potential Mechanism of Action
Improving Circadian Function
Mechanisms of action in light therapy and PD are not known. However, a leading hypothesis is that specialized light may be acting through improved circadian function.
Circadian rhythms are the daily biological cycles that regulate physical, mental and behavioral function. Circadian dysfunction is a hallmark several neurodegenerative diseases, including Alzheimer’s, Huntington’s and Parkinson’s. In Parkinson’s, circadian rhythms may be severely blunted, and PD medications may cause these rhythms to run faster than normal.
Light is known to be the strongest entrainer of circadian rhythms. Our specialized phototherapy technology is designed to address circadian dysregulation in PD and may improve motor and non-motor function and help PD patients enjoy greater quality of life.
The Cycle of Innovation, Clinical Research, and Improved Lives
For decades our founders innovated treatments of specialized light therapy in circadian-related neuropsychiatric disorders. They researched the new product’s safety and efficacy and delivered those innovations to and blessed the lives of hundreds of thousands of patients.
The founders of PhotoPharmics have applied their expertise to circadian dysregulation in neurodegenerative disease. This resulted in a new platform technology which was adapted into a safe and convenient product for Parkinson’s patients. PhotoPharmics is currently validating this product in robust clinical research. With demonstrated safety and efficacy, we anticipate these products will become widely available for people with Parkinson’s.
In addition to improving the lives of Parkinson’s patients we have reason to believe that specialized phototherapy can contribute to the treatment of other neurodegenerative diseases. PhotoPharmics is now applying what we’ve learned in Parkinson’s into new products and additional disease states. We will look to validate those products in robust clinical research, and if successful, get the solutions into the hands of individuals who suffer from these neurodegenerative diseases.